Contineum Therapeutics IPO

Contineum is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications with high unmet need.

Register for Details

For more details on financing and valuation for Contineum Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Contineum Therapeutics

Forge green plus iconForge green minus icon

What is Contineum Therapeutics's funding to date?

Contineum Therapeutics has raised $133.61MM to date.
Forge green plus iconForge green minus icon

When was Contineum Therapeutics founded?

Contineum Therapeutics was founded in 2017.

Contineum Therapeutics Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
2/11/2021 Series C $80.4MM raised $XXX.XX $XXX.XX
12/18/2019 Series B $31.99MM raised $XXX.XX $XXX.XX
4/4/2018 Series A and A-1 $21.22MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Jun 14, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.